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Abstract
Background: Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is recommended
by WHO to prevent malaria in African pregnant women. The spread of SP parasite resistance has raised concerns regarding
long-term use for IPT. Mefloquine (MQ) is the most promising of available alternatives to SP based on safety profile, long
half-life, and high efficacy in Africa. We evaluated the safety and efficacy of MQ for IPTp compared to those of SP in HIV-
negative women.
Methods and Findings: A total of 4,749 pregnant women were enrolled in an open-label randomized clinical trial
conducted in Benin, Gabon, Mozambique, and Tanzania comparing two-dose MQ or SP for IPTp and MQ tolerability of two
different regimens. The study arms were: (1) SP, (2) single dose MQ (15 mg/kg), and (3) split-dose MQ in the context of long
lasting insecticide treated nets. There was no difference on low birth weight prevalence (primary study outcome) between
groups (360/2,778 [13.0%]) for MQ group and 177/1,398 (12.7%) for SP group; risk ratio [RR], 1.02 (95% CI 0.86–1.22; p= 0.80
in the ITT analysis). Women receiving MQ had reduced risks of parasitemia (63/1,372 [4.6%] in the SP group and 88/2,737
[3.2%] in the MQ group; RR, 0.70 [95% CI 0.51–0.96]; p= 0.03) and anemia at delivery (609/1,380 [44.1%] in the SP group and
1,110/2743 [40.5%] in the MQ group; RR, 0.92 [95% CI 0.85–0.99]; p= 0.03), and reduced incidence of clinical malaria (96/
551.8 malaria episodes person/year [PYAR] in the SP group and 130/1,103.2 episodes PYAR in the MQ group; RR, 0.67 [95%
CI 0.52–0.88]; p= 0.004) and all-cause outpatient attendances during pregnancy (850/557.8 outpatients visits PYAR in the SP
group and 1,480/1,110.1 visits PYAR in the MQ group; RR, 0.86 [0.78–0.95]; p= 0.003). There were no differences in the
prevalence of placental infection and adverse pregnancy outcomes between groups. Tolerability was poorer in the two MQ
groups compared to SP. The most frequently reported related adverse events were dizziness (ranging from 33.9% to 35.5%
after dose 1; and 16.0% to 20.8% after dose 2) and vomiting (30.2% to 31.7%, after dose 1 and 15.3% to 17.4% after dose 2)
with similar proportions in the full and split MQ arms. The open-label design is a limitation of the study that affects mainly
the safety assessment.
Conclusions: Women taking MQ IPTp (15 mg/kg) in the context of long lasting insecticide treated nets had similar
prevalence rates of low birth weight as those taking SP IPTp. MQ recipients had less clinical malaria than SP recipients, and
the pregnancy outcomes and safety profile were similar. MQ had poorer tolerability even when splitting the dose over two
days. These results do not support a change in the current IPTp policy.
Trial registration: ClinicalTrials.gov NCT 00811421; Pan African Clinical Trials Registry PACTR 2010020001429343
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Introduction
As the scourge of malaria continues, special considerations
regarding the management of the infection in the most vulnerable
groups are needed to achieve maximum safety and efficacy of
control strategies. Owing to not yet well established physiological
reasons, pregnant women are more susceptible to the effects of
malaria infection with increased associated morbidity and
mortality both in the mother and her newborn [1–4]. Thus,
pregnant women are a vulnerable group for malaria who require
particular attention [5], which is especially relevant in the African
region where nearly 30 million pregnancies occur every year in
areas where there is stable transmission of Plasmodium falciparum,
the most deleterious of the human malaria parasites [3]. Because
of this concern, pregnant women in Africa are currently the only
population group in whom malaria preventive measures are
routinely implemented. These measures rely on the use of long-
lasting insecticide treated nets (LLITNs) and the administration of
intermittent preventive treatment in pregnancy with sulfadoxine-
pyrimethamine (IPTp-SP) [6]. Until the last World Health
Organization (WHO) revision of the guidelines, it was recom-
mended that women should receive at least two doses of IPTp-SP
starting from the second trimester and at least one month apart to
prevent malaria during pregnancy [6,7]. These guidelines apply
only to HIV negative women, while for HIV positive women IPT-
SP is contraindicated to avoid safety interactions with cotrimox-
azole prophylaxis [7,8].
IPTp-SP has been shown to reduce low birth weight (LBW)
deliveries and maternal morbidity [1,9]. Because it is delivered
through an existing health infrastructure such as the antenatal care
(ANC) clinic scheme and due to the low cost of SP, IPTp remains
a cost-effective intervention even in areas of relatively low malaria
transmission and reduced efficacy levels of the drug due to parasite
resistance [10]. However, drug resistance can evolve rapidly and a
reduction in the efficacy of SP would reduce its beneficial impact
on clinical delivery outcomes and worsen the cost-effectiveness of
the intervention [11]. It has been shown that within certain
parameters improving the antimalarial’s efficacy would ameliorate
the cost-effectiveness of the intervention despite an increase in its
cost [10]. Thus, the evaluation of alternative antimalarial drugs to
SP for IPTp is needed for optimal health decision-making
especially in resource-limited countries.
The decision process on the best candidate to replace SP for
IPTp needs to consider that a potential alternative drug should
have at least three main attributes, namely: have a long half-life to
maximize the prophylactic effect, be administered in single dose to
ensure compliance, and have an acceptable reproductive toxicity
profile [12,13]. Of all the available antimalarial drugs, mefloquine
(MQ), from the arylaminoalcohols group, is currently the one that
matches these criteria. Contrary to the situation in parts of
Southeast Asia, MQ retains high antimalarial activity in Africa as
evidenced by both in vitro and in vivo studies [14–17]. MQ is
among the very few antimalarials considered safe throughout
pregnancy to be recommended by the WHO and the US Centers
for Disease Control (CDC) for chemoprophylaxis for pregnant
women of all gestational ages travelling in malaria endemic
regions. It has recently been reclassified as pregnancy category B
by the US Food and Drug Administration (FDA) (‘‘Animal
reproduction studies have failed to demonstrate a risk to the foetus
and there are no adequate and well-controlled studies in pregnant
women’’) [16,18]. Regarding drug tolerability and safety, MQ has
been associated with mild and transient vomiting and dizziness as
well as rare neurological and psychological severe adverse effects
[19]. Evidence from studies in patients with uncomplicated
malaria from Southeast Asia showed that MQ tolerability is
improved by splitting the total dose over two days of administra-
tion [20]. However, it is unknown whether these results could be
extrapolated when MQ is administered to asymptomatic or un-
infected pregnant women. One concern in relation to the use of
MQ in pregnancy has been the potential association of the drug
with an increased risk of stillbirths. This finding was reported in a
retrospective analysis among 208 Karen women who received MQ
for malaria treatment [21]. This finding was not confirmed in
studies including a larger prospective clinical trial of MQ
prophylaxis in Malawian pregnant women, but the impact of
MQ on birth outcomes remains controversial [22].
The information to date regarding MQ as IPTp is limited to
two trials carried out in Benin, which have provided encouraging
results [23,24]. In light of the lack of available alternatives to
replace SP it is necessary to confirm that MQ constitutes an
adequate alternative for IPTp in a large study. In order to evaluate
the safety and efficacy of MQ as IPTp in comparison to SP, in
HIV negative women, a randomized controlled trial was
conducted in four sub-Saharan countries in the context of LLITN
use. The study also assessed the tolerability of MQ when
administered as a split dose over two days.
Methods
Ethics Statement and Participants’ Safety
The study protocol and informed consent forms were reviewed
and approved by the Ethics Committees from the Hospital Clı´nic
of Barcelona (Spain), the Comite´ Consultatif de De´ontologie et
d’E´thique (CCDE) from the Institut de Recherche pour le
De´veloppement (IRD, in France), and all local regulatory
authorities and National Ethics Review Committees from each
malaria endemic country participating in the study (Table S1).
The trial was conducted under the provisions of the Declaration of
Malaria in Pregnancy Preventive Alternative Drugs
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donated by Vestergaard Fransen.
(ref. CM07/0015 and CM11/00278, respectively). The CISM receives core funding from the Spanish Agency for International Cooperation (AECI). LLITNs (Permanet) were
Helsinki and in accordance with Good Clinical Practices guidelines
set up by the WHO and by the International Conference on
Harmonization. An independent Data Safety Monitoring Board
(DSMB) was created prior to the beginning of the trial and regularly
reviewed and monitored the safety data collected. The trial was
registered prior to the enrolment of the first participant in both the
ClinicalTrials.gov (NCT0081121) and in the Pan African Clinical
Trials (PACTR2010020001429343) registries.
Study Area and Population
The study was conducted between 2009 and 2013 in four sub-
Saharan countries: Benin (Allada, Se´kou, and Attogon), Gabon
(Lambare´ne´ and Fougamou), Tanzania (Makole and Chamwino),
and Mozambique (Manhic¸a and Maragra). The characteristics of
each site are shown in Table S2.
Study Design
The study was designed as an open-label, randomized, three-arm
trial to compare two-dose MQ with two-dose SP for IPTp, and to
compare the tolerability of two different MQ administration
regimens in the context of LLITN use. The three study arms were:
(1) IPTp with SP, (2) IPTp with MQ (15 mg/kg) given once as a full
dose, and (3) IPTp with MQ (15 mg/kg) split over two days. The
primary endpoint of the study was the prevalence of LBW babies
(,2,500 g). On the basis of previous estimations in the study sites
[9,25], of a LBW prevalence of 12% in the context of IPTp-SP and
LLITN use and an estimated 25% reduction to 9% in the MQ
group, 1,257 women in the SP arm and 2,514 women equally split
between the two MQ arms were needed to show superiority of MQ
compared to SP in reducing LBW rates, at the 5% two-sided level of
significance with 80% statistical power (Texts S1 and S2).
Enrolment and Interventions
Pregnant women of all gravidities attending an ANC clinic for
the first time and who had not received IPTp during their current
pregnancy were invited to participate in the study after provision
of informed consent. Inclusion criteria were: permanent residence
in the study area, gestational age #28 weeks, negative HIV-testing
at recruitment, absence of history of allergy to sulfa drugs or MQ,
absence of history of severe renal, hepatic, psychiatric, or
neurological disease, and of MQ or halofantrine treatment in
the preceding 4 weeks. Gestational age was determined from
fundal height measurement by bimanual palpation. Women not
meeting inclusion criteria received standard ANC following
national guidelines. Hemoglobin (Hb), HIV test and the syphilis
rapid plasma reagin test (RPR) were assessed at the first antenatal
visit as per local standard procedures. In Mozambique and
Tanzania, HIV-infected women were invited to participate in a
Figure 1. Trial profile (modified ITT cohort).
doi:10.1371/journal.pmed.1001733.g001
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placebo-controlled trial evaluating MQ IPTp in women on daily
cotrimoxazole prophylaxis [26]. The allocation of the participants
to the study arms was done centrally by randomization stratified
by country according to a 1:1:1 scheme. The sponsor’s institution
biostatistician produced the computer-generated randomization
list for each recruiting site. Treatment allocation for each
participant was concealed in opaque sealed envelopes that were
opened only after recruitment. Study participants were assigned a
unique study number linked to the allocated treatment group. All
participants received a LLITN (PermaNet, Vestergaard Fransen)
at enrolment as part of the study intervention.
Following physical examination, recruited women with gesta-
tional age$13 weeks received their first dose of IPTp (either SP or
MQ) under supervision. Women allocated to the SP group
received standard IPTp (three tablets of the fixed combination
therapy containing 500 mg of sulfadoxine and 25 mg of
pyrimethamine, Malastop, Sterop), whereas participants allocated
to the MQ groups received 15 mg/kg of the drug (Lariam, Roche,
tablets of 250 mg of MQ base). The number of tablets was
calculated according to body weight, thus a woman weighing
70 kg would receive four and a quarter tablets. The maximum
dosage would not exceed 1,500 mg of MQ base corresponding to
six tablets. For women allocated to the MQ split dose group, the
15 mg/kg dose was divided into two halves and administered over
two consecutive days with the second half dose administered either
at the ANC clinic or at home (by study personnel). All study
participants were observed for 60 minutes following IPT admin-
istration. Women who vomited within the first 30 minutes were
provided a second full IPT dose and those vomiting 30–
60 minutes after drug intake were given a half replacement dose.
Home visits by field workers were done two days after IPTp
administration to assess drug tolerability and correct LLITN use.
The second IPTp-SP/MQ administration was given at least one
month later than the first one.
Follow-up
Women were encouraged to attend the ANC clinic whenever
they had any health complaint. Health care was free of charge and
in general there was little availability of antimalarial drugs over the
counter at all sites. A health facility-based passive surveillance
system was established at each site to capture unscheduled visits of
the study participants during the study follow-up. At each
unscheduled visit, a standardized questionnaire was completed
documenting signs and symptoms. Blood smears were prepared
for malaria parasite examination and hemoglobin was measured if
there were current or reported symptoms and/or signs suggestive
of malaria. Clinical malaria episodes were treated with oral
quinine or artemether-lumefantrine in the first and subsequent
trimesters, respectively, for uncomplicated malaria, and with
parenteral quinine for severe malaria. Solicited and unsolicited
Table 1. Baseline characteristics.
Characteristics SP MQ Full Dose MQ Split Dose
N Participants 1,576 1,579 1,590
Countrya
Benin 394 391 397
Gabon 391 394 395
Mozambique 392 395 396
Tanzania 399 399 402
Age (years)b 24.8 (6.3) [1,576] 24.7 (6.3) [1,579] 24.5 (6.0) [1,590]
Graviditya
Primigravidae 460 (29) 458 (29) 460 (29)
1–3 previous pregnancies 778 (49) 786 (50) 826 (52)
4 or more pregnancies 338 (21) 335 (21) 304 (19)
Weight (kg)b 59.9 (11.1) [1,576] 59.8 (11.0) [1,579] 59.6 (11.3) [1,590]
Height (cm)b 158.1 (8.0) [1,575] 158.3 (6.0) [1,578] 157.5 (8.5) [1,588]
MUAC index (cm)b 26.4 (3.5) [1,570] 26.5 (3.6) [1,574] 26.4 (3.6) [1,587]
Gestational age (weeks)c 21.0 (7.0) [1,575] 21.0 (7.0) [1,579] 21.0 (7.0) [1,590]
Gestational age in categoriesa
First trimester 133 (8) 143 (9) 123 (8)
Second trimester 1,113 (71) 1,095 (69) 1,124 (71)
Third trimester 329 (21) 341 (22) 343 (22)
Literatea (can read and/or write) 1,101 (70) 1,107 (70) 1,093 (69)
Syphilis test positivea 20 (1) 19 (1) 30 (2)
Hemoglobin (g/dl)b 10.6 (1.5) [1,572] 10.6 (1.5) [1,569] 10.5 (1.5) [1,585]
Overall anemia at baseline (Hb,11 g/dl)a 946 (60) 914 (58) 952 (60)
ITT cohort.
an (column percentage).
bArithmetic mean (SD) [n].
cMedian (IQR) [n].
MUAC, middle upper arm circumference.
doi:10.1371/journal.pmed.1001733.t001
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adverse events (AEs) were assessed. The former was done by
directed questioning of malaria related signs and symptoms during
unscheduled visits, whereas the latter were assessed through open
questioning during scheduled visits. Women who were withdrawn
from the study received routine ANC treatment.
At delivery, women’s peripheral blood, cord blood, and
placental (biopsy and impression smears) samples were collected
for hematological and parasitological evaluation. Newborns were
weighed (weekly calibrated scales, either digital or three beam
balances), and their gestational age at birth evaluated using the
Ballard’s score [27]. Newborn weights not captured at birth but
within the first week of life were estimated using a linear regression
model (Figure S1) [28]. One month after the end of pregnancy, a
capillary blood sample from the mother was collected for malaria
parasite determination. LLITN use was assessed at each study visit
by questions about use the preceding night.
Laboratory Methods
At enrolment, HIV and syphilis serostatus were assessed at each
site according to local standard procedures using rapid diagnostic
tests (Table S2). Hemoglobin was determined using mobile devices
in capillary blood sample (HemoCue [www.eurotrol.com] and
Hemocontrol [www.ekfdiagnostics.com]). Thick and thin blood
films were stained and read for Plasmodium species detection
according to standard, quality-controlled procedures [29,30].
Tissue samples were collected from the maternal side of the
placenta and placed into 10% neutral buffered formalin. Biopsies
were processed, stained, and examined following standard proce-
dures [31]. Impression smears from the placental blood were stained
with Giemsa and read following a standardized protocol [32,33].
Data Management, Statistical Methods, and Definitions
The quality of the data recorded in the study source
documents and case report forms (CRFs) were monitored
regularly following Good Clinical Practices principles by the
trials’ clinical monitor before their shipment to the centralized
database in Manhic¸a, Mozambique. Data were double-entered
using the OpenClinica Enterprise software for clinical data
management (www.openclinica.com). The analysis was done
on the modified Intention to Treat (ITT) cohort that included
all recruited women who met the inclusion criteria and had
data on the specific outcomes, and the According to Protocol
(ATP) cohort that included all women who had received the
two doses of IPTp according to the pre-specified schedule, had
delivered singletons, and whose babies’ weight (including
stillbirths) had been recorded. The safety cohort was defined
as all recruited women who had received at least one dose of
IPTp and whose data for analysis were available. The analysis
of safety and tolerability was made on the safety cohort. The
ITT analyses were adjusted by country. The analyses in the
ATP cohort were adjusted by baseline covariates (seasonality,
gestational age, gravidity, anemia, literacy, and middle upper
arm circumference). To include seasonality in the adjusted
analysis, the duration of recruitment was divided into eight
periods, and the interaction terms between the periods of
recruitment and country were included in the model, which
allows modelling the effect of period in each country
independently. Proportion of low birth weight babies (,
2,500 g at birth) were compared between groups using a
modified binomial regression [34]. Only birth weights
captured during the first week of life were included in the
analysis. The interpretation of the statistical analysis for
efficacy followed a sequential approach [35]. First, based on
the confidence intervals, non-inferiority between the propor-
tion of LBW in the MQ (combined MQ full and split dose
groups) and the SP groups was evaluated assuming a 25%
reduction in LBW prevalence as non-inferiority margin. If
non-inferiority between MQ and SP was achieved, then a
Table 2. Low birth weight (,2,500 g at birth) rates by treatment group and country.
Treatment Group and
Country SP MQ RR 95% CI p-Value
n/N Percent n/N Percent
Overall prevalence of LBW
ITT 177/1,398 12.7 360/2,778 13.0 1.02 (0.86–1.22) 0.80
ATP 128/1,289 9.9 221/2,146 10.3 1.03 (0.84–1.26) 0.80
Benin
ITT 47/349 13.5 110/703 15.6 1.16 (0.82–1.64) 0.39
ATP 33/322 10.2 70/629 11.1 1.06 (0.72–1.57) 0.77
Gabon
ITT 54/331 16.3 112/652 17.2 1.05 (0.77–1.44) 0.75
ATP 36/291 12.4 52/384 13.5 1.04 (0.70–1.54) 0.85
Mozambique
ITT 37/360 10.3 66/712 9.3 0.90 (0.60–1.36) 0.62
ATP 28/342 8.2 44/507 8.7 0.99 (0.64–1.55) 0.98
Tanzania
ITT 39/358 10.9 72/711 10.1 0.93 (0.63–1.36) 0.71
ATP 31/334 9.3 55/626 8.8 0.95 (0.63–1.45) 0.83
ITT analysis adjusted by country. Interaction country6treatment: x2: 1.22 with 3 degrees of freedom p=0.766.
ATP analysis adjusted by baseline variables (country, seasonality, gestational age, gravidity, anemia, literacy, and middle upper arm circumference [MUAC]). Interaction
country6treatment: x2: 0.31 with 3 degrees of freedom p= 0.959.
doi:10.1371/journal.pmed.1001733.t002
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superiority interpretation comparing the groups was planned.
The statistical analysis plan is available (Text S3).
Malaria infection was defined as the presence of asexual P.
falciparum parasites of any density in a blood smear. A clinical
malaria episode was defined as the latter plus any sign and/or
symptom suggestive of malaria including: fever (axillary
temperature $37.5uC) in the last 24 hours, and/or pallor
and/or arthromyalgias and/or headache and/or history of
convulsions [36]. The incidence of all clinical malaria episodes
was compared between groups using a negative binomial
regression allowing for interdependence between episodes
within the same subject, excluding from the time at risk the
28 days after a malaria episode. Failure curves were produced
using the Kaplan-Meier methodology. Placental infection was
defined as the presence of parasites with or without pigment in
the histological examination, or in the impression smear [31–
33]. Anemia was defined as a Hb level ,11 g/dl and severe
anemia as Hb,7 g/dl. Immediate tolerability to study drugs
was assessed as observed vomiting within one hour of drug
administration. An AE was defined as any untoward medical
occurrence in a study participant, to whom the study drug was
administered, including occurrences, which are not necessarily
caused or related to that drug. Serious adverse events (SAEs)
were defined as an AE that met any of the following criteria: (1)
results in death, (2) is life-threatening, (3) requires hospitaliza-
tion (or prolongation of existing hospitalization), (4) results in
disability/incapacity, (5) is a congenital anomaly, or (6) any
event of special interest (including miscarriage and stillbirths of
women not admitted to hospital) [37]. The proportions of
women with an AE or a SAE were presented by treatment
group with 95% confidence intervals and p-values were
calculated by Fisher-exact text. For safety and tolerability
outcomes it was considered that there was no evidence of
significant difference between treatment groups if the 95%
confidence intervals overlapped. Data analysis was performed
using Stata statistical software version 13 (Stata Corp.).
Results
Baseline Characteristics of Study Participants
Figures 1 and S2 show the trial profile in the ITT and ATP
cohorts, respectively. Overall, 4,749 pregnant women were
randomized to receive IPTp (1,578 were allocated to SP, 1,580
to MQ full dose, and 1,591 to MQ split dose). Four women were
not included in the ITT cohort: two did not finalize recruitment
process, one was not pregnant, and one was recruited twice and
only the first enrolment was included in the analysis. The main
reasons for no enrolment into the trial were no permanent
residence in the study area (41%) and gestational age.28 weeks
(28%). The overall refusal rate for trial participation was 18%.
Baseline characteristics were similar for women in the three
treatment groups (Table 1). Syphilis prevalence was between 1%
and 2% and anemia prevalence between 58% and 60%. Mean
gestational age was 21 (standard deviation [SD] 7) weeks at the
Figure 2. Birth weight distribution by study country and IPTp group. Newborn weights not captured at birth but within the first week of life
were estimated using a linear regression model.
doi:10.1371/journal.pmed.1001733.g002
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first IPTp dose and 26 (SD 6) weeks at the second IPTp dose.
Median time between first and second dose was 35 (interquartile
range [IQR] 12) days, and median time between the last dose and
delivery was 94 days (IQR 48).
Primary Endpoint
A total of 4,176 birth weights were collected and analyzed in the
ITT cohort (81.4% were captured at birth; overall, 2.7% from
stillbirths, 3.7% from twins), whereas 3,435 birth weights were
analyzed in the ATP cohort (83.7% captured at birth; 2.5% from
stillbirths, none from twins). There were no significant differences
between the MQ and SP groups in either the prevalence of LBW
infants (13.0% in the overall MQ group and 12.7% in the SP
group, risk ratio [RR], 1.02 [95% CI 0.86–1.22; p= 0.80]) or in
mean birth weight (Tables 2 and 3). On the basis of the confidence
interval, non-inferiority could be accepted between the MQ and
the SP groups at the pre-specified 25% margin for reduction in
LBW prevalence in the ITT analysis, but not in the ATP analysis
(Table 2). No difference in the prevalence of LBW was observed
either between the full and split MQ dose (RR, 1.04 [95% CI
0.84–1.28]). The results were similar in the ATP adjusted (RR,
1.03 [95% CI 0.84–1.26]) and unadjusted (RR, 1.05 [95% CI
0.85–1.29]) analyses. Figure 2 shows the birth weight distribution
by country and treatment group.
Secondary Endpoints
The risk of maternal peripheral malaria parasitemia at delivery
was 30% lower in women who received MQ compared to those
who received SP (RR, 0.70 [95% CI 0.51–0.96]; p= 0.03). The
risk of overall maternal anemia (Hb,11 g/dl) at delivery was also
lower (44.1% in the SP group versus 40.5% in the MQ group
[RR, 0.92 (95% CI 0.85–0.99)]; p= 0.03) and the mean Hb was
higher in women who received IPTp-MQ compared to those in
the SP group, although these differences were only significant in
the ITT analysis (Table 3). The frequency of severe anemia was
also lower in women receiving MQ although the difference did not
reach statistical significance (Table 3).
There were no differences between groups in the prevalence of
placental infection, neonatal parasitemia, neonatal anemia, or
maternal peripheral parasitemia one month after delivery
(Table 3). Results stratified by country can be found in Tables
S3, S4, S5 and placental histology results by treatment in
Table S6. The incidence of clinical malaria episodes and of all-
cause outpatient attendances during pregnancy were signifi-
cantly lower in women receiving IPTp-MQ compared to those
receiving IPTp-SP (RR, 0.67 [95% CI 0.52–0.88]; p = 0.004
and RR, 0.86 [0.78–0.95]; p = 0.003, respectively) (Figure 3;
Table 4). The incidence of all-cause hospital admissions was
lower in the MQ group although not statistically significantly
Figure 3. Time to first episode of clinical malaria. ITT cohort. Kaplan Meier graph.
doi:10.1371/journal.pmed.1001733.g003
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different (RR, 0.88 [0.68–1.14]; p = 0.35) (Table 4). The
overall reported use of LLITN at delivery was of 90% and of
96% one month after the end of pregnancy, with no difference
between study groups.
Safety
There was no difference in the prevalence of adverse pregnancy
outcomes (including miscarriages, stillbirths, and congenital mal-
formations) between groups (Table 5). The number of SAEs,
including maternal and neonatal deaths, was also similar among the
three study arms. The number of women who had SAEs considered
as drug-related by the site investigator was higher in the MQ
groups: one in the SP group (0.1%; a miscarriage), 11 in the MQ
full-dose group (0.7%; one urinary tract infection, one generalized
urticaria, one stillbirth, one premature delivery, two miscarriages,
and five vomiting episodes), and ten in the MQ split-dose group
(0.6%; two miscarriages, two stillbirths, three preterm delivery, one
malaria, and three vomiting episodes). Serious adverse pregnancy
outcomes considered as drug-related by the study investigators were
carefully reviewed by the trial’s independent DSMB, which
concluded that a causal relationship between the drug and these
SAEs could not be established. No serious neurological AEs were
reported among study participants. The frequency of non-serious
reported sleeping disorders was higher in the MQ group (79/3,113,
2.5%; [95% CI 2.0–3.2]) than in the SP group (12/1,561, 0.8%
[95% CI 0.4–1.3]). Two women with unknown psychiatric
antecedents attempted suicide in the SP group.
Tolerability
The immediate tolerability of IPTp was poorer in the two MQ
groups as compared to the SP group, with no difference between
the full and split-dose groups (Table 6). The most frequently
reported related AEs following the first MQ administration were
dizziness (33.9% and 35.5% in the full and split-dose groups,
respectively) and vomiting (31.7% and 30.1% in the full and split
dose groups, respectively) (Table 7). The majority of these AEs
started within 48 hours after drug administration. The mean
duration of the aforementioned AEs was one day (IQR 2) and over
70% were classified as mild (Table 8). The prevalence of dizziness
and vomiting related to MQ was reduced at the second IPTp
administration compared to the first one (Figure 4; Table 7).
Table 9 shows the reported AEs by system organ class and
treatment group and Table 10 the list of SAEs related to the drug.
Adherence with IPTp
The second IPTp administration was not given to 7% (111/
1,559), 11% (178/1,550), and 12% (193/1,562) of women who
had received the first administration of SP, MQ full, and split-
dose, respectively. In addition, in the MQ split-dose group, 7%
(101/1,562) and 8% (108/1,369) of the women did not receive the
second half dose at the first and second IPTp administrations,
respectively. The proportion of women who had a related AE
within two weeks after receiving the first IPTp administration and
who did not receive the second IPTp administration was 7% (23/
293), 16% (116/721), and 14% (109/769) in the SP, MQ full, and
split dose groups, respectively.
Discussion
This multicentre open-label randomized trial that compared
two doses of IPTp with MQ (15 mg/kg dose) versus SP in HIV-
negative pregnant women using LLITNs found no differences in
the prevalence of LBW between the two intervention groups.
However, the prevalences of maternal parasitemia and anemia at
delivery were significantly lower in women receiving MQ
compared to SP recipients. The study also found that the
incidence of clinical malaria and all-cause outpatient visits during
pregnancy was reduced in the MQ group. On the other hand, the
tolerability of MQ was poorer compared to that of SP especially
for the AEs that have been typically related with this drug such as
dizziness and vomiting.
The lack of beneficial effect of MQ as compared to SP in
reducing the prevalence of LBW might be explained by the fact
that all women were protected by efficacious malaria control
strategies [38], together with a decreased malaria transmission
during the study period in some study sites. These factors resulted
in a reduced exposure to the parasite reflected by the low
prevalence of peripheral parasitemia at delivery and placental
infection in all intervention groups. These circumstances may have
decreased the contribution of malaria (which is one of the many
factors affecting birth weight in endemic areas) to LBW,
compromising the statistical power to detect differences between
groups. Some previous chemoprophylaxis and IPT trials in
pregnant women have documented a lack of effect on birth
weight of these malaria preventive strategies [9,23,39]. Another
potential explanation for diluting the difference in birth weight
outcomes might be that women were on average two months
Table 8. Severity of reported vomiting and dizziness by treatment group.
Grade of Severity SP MQ Full MQ Split
n Percent n Percent n Percent
Vomiting related to medication
Milda 145 86.31 511 68.68 497 71.10
Moderateb 22 13.10 194 26.08 186 26.61
Severec 1 0.60 39 5.24 16 2.29
Dizziness related to medication
Mild 176 88.44 559 72.98 660 76.57
Moderate 21 10.55 175 22.85 185 21.46
Severe 2 1.01 32 4.18 17 1.97
aMild: awareness of sign or symptom, but easily tolerated.
bModerate: discomfort enough to cause interference with usual activity.
cSevere: incapacitating with inability to work or perform usual activity or patients at risk of death at the time of the event.
doi:10.1371/journal.pmed.1001733.t008
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without the protection of an antimalarial since the last IPTp
administration until delivery. This possibility would support the
addition of more IPTp administrations as it is now more clearly
recommended [7]. Since LBW is only one of the deleterious
consequences of malaria in pregnancy and is prone to multiple
confounding, it can be argued that other study outcomes might be
better suited to reflect the efficacy of malaria control strategies in
pregnant women [7]. This consideration suggests the need to shift
the endpoint in the assessment of the impact of malaria control
measures in pregnancy to more upstream malaria-related
Figure 4. Reported medication-related adverse events.
doi:10.1371/journal.pmed.1001733.g004
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outcomes than birth weight, such as parasite prevalence and
incidence of clinical episodes. In this study there were significant
differences in the prevalence of parasitemia and overall anemia at
delivery, which were lower in women who had received MQ
compared to those who had received SP. Importantly, the
incidence of clinical malaria episodes and overall outpatient visits
during pregnancy were also significantly reduced in the two MQ
arms. These two outcomes are frequently overlooked in the
evaluation of malaria control strategies in pregnant women in the
assumption that the public health benefit should be only or mainly
reflected on the effects on the newborn. Differences in the
magnitude of reduction in the incidence of clinical malaria and
outpatient visits have also been reported in malaria prevention
trials in children [40]. Interestingly, the figure showing the
incidence of clinical malaria during pregnancy indicates that the
risk of malaria rises after the second IPTp administration, and that
a third IPTp administration would be beneficial to improve
protection against the infection, which supports the new policy for
IPTp [7].
A finding that has generated much concern and debate in
relation with the use of MQ in pregnancy was the report from a
retrospective analysis in Thailand documenting an increased risk
of stillbirths in 208 pregnant women treated with MQ [21]. This
observation was not confirmed in larger randomized trials and
descriptive studies [22,41,42]. In the present study, the safety
profile of IPTp-MQ in terms of the number of SAEs and adverse
pregnancy outcomes was similar to that of SP. The observed
discrepancy between the investigator’s assessment of the drug
relatedness of serious adverse pregnancy outcomes and the final
judgment made by the trial’s DSMB is most likely due to the open
label design of the study, which may have influenced the
assignment of causality made by the clinical investigator.
Given the lack of an appropriately validated tool for rural
African populations, a detailed screening of neurological and
psychological problems was not carried out as part of the study.
Although there were no reports of depression or other serious
neurological problems, it cannot be ruled out that they may have
occurred. The only serious adverse psychiatric events reported in
the study were suicide attempts in two women who had received
SP. The other frequently reported AE associated with MQ
exposure among individuals travelling in malaria endemic regions
on weekly chemoprophylaxis [43–46] is sleeping disorders. In this
study, 82 women in the MQ groups and 12 in the SP group
reported sleeping disorders (such as insomnia and bad dreams). As
with the above-mentioned related AEs, it is difficult to disentangle
whether these reports indeed reflect a side effect, or alternatively
can be explained by a potential bias due to the open trial design
[47]. Previous studies using the same MQ dose (15 mg/kg) have
found the same trend although the differences between treatments
were not statistically significant [23].
In agreement with a recent IPTp trial, MQ presented a poorer
tolerability than SP with higher frequencies of related AEs such as
dizziness and vomiting [23]. While the frequency of other AEs not
previously related to MQ such as headache were similar after both
IPTp administrations, the frequency of dizziness, vomiting,
nausea, and weakness decreased after subsequent MQ doses. This
finding could be due to a selection of the women more susceptible
to experience dizziness and vomiting not receiving the second MQ
Table 10. List of possibly/probably related SAEs.
Number Treatment Causality MEDdra_code
1 MQ Full Possible Urinary tract infection
2 MQ Split Possible Spontaneous abortion
3 MQ Split Possible Stillbirth
4 MQ Split Possible Stillbirth
5 MQ Full Possible Generalized urticarial
6 MQ Full Possible Stillbirth
7 MQ Full Possible Other preterm infants, 500–749 g
8 MQ Split Possible Other preterm infants, 500–749 g
9 MQ Full Possible Spontaneous abortion
10 MQ Full Probable Vomiting
11 MQ Full Probable Vomiting
12 MQ Split Probable Vomiting
13 MQ Split Probable Malaria
14 MQ Split Probable Vomiting
15 MQ Full Probable Vomiting
16 MQ Full Probable Vomiting
17 SP Possible Spontaneous abortion
18 MQ Split Probable Vomiting
19 MQ Full Probable Vomiting
20 MQ Full Possible Spontaneous abortion
21 MQ Split Possible Other preterm infants, 500–749 g
22 MQ Split Possible Spontaneous abortion
23 MQ Split Possible Other preterm infants, 500–749 g
doi:10.1371/journal.pmed.1001733.t010
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administration. However a reduced frequency of related AEs with
subsequent doses has been observed in previous chemoprophylaxis
and IPT trials with MQ in pregnancy, as well as in reports from
non-pregnant individuals travelling in malaria endemic regions
indicating that a true tolerance effect might play a role [23,45,48].
Unlike previous studies investigating different MQ regimens,
splitting the administration of MQ over two consecutive days did
not translate into a better tolerability of the drug, although the
antimalarial efficacy was maintained [20]. In addition, adherence
with IPTp-MQ was considerably lower in those women assigned
to the split dose. This finding strongly emphasizes that future
candidate drugs for IPTp should be evaluated as single dose
administration with observed intake to ensure optimal adherence
in otherwise asymptomatic pregnant women.
The prevalence of syphilis was very low in the study participants,
which may reflect an improved effectiveness of ANC syphilis control
programs [49], and it is possibly accompanied by a reduction in the
prevalence of other sexually transmitted infections in pregnancy.
This finding may be helpful in the discussion and evaluation of
alternatives to SP with more complex drug combinations that have
the objective of concomitantly treating sexually transmitted diseases
while preventing malaria [50].
In this study, and following the same rationale as for SP, the
dosage of 15 mg/kg of MQ was chosen as it is recommended for
malaria treatment in areas of low parasite resistance [23]. A
dosage of MQ of 125 mg used in a previous weekly chemopro-
phylaxis study in Karen pregnant women showed comparable
tolerability to the placebo group [39]. It is possible that a lower
dosage than that used in this study would have been better
tolerated maintaining similar antimalarial efficacy.
The main limitation of this study is its open-label design, which
may have led to biases in the assessment of outcomes, especially
those of safety assessing adverse effects commonly ascribed to the
study drugs [51]. However, given the differences in scheme and
dosage between treatments, a double-blind design was considered
to be difficult and not acceptable for the participants given the
large quantity of tablets the women would have needed to take.
From the study results, it can be concluded that women taking
two IPTp administrations of MQ at the treatment dosage of
15 mg/kg, and in the context of high LLITN use, had similar
prevalence rates of LBW as women taking SP. MQ recipients had
less clinical malaria than SP recipients and the pregnancy
outcomes and safety profile were similar. MQ tolerability was
poorer than that of SP even when splitting the dose over two days.
These results do not support a change in the current recom-
mended IPTp policy [7,52].
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Editors’ Summary
Background. Half the world’s population is at risk of
malaria, a mosquito-borne parasitic disease that kills about
600,000 people every year. Most of these deaths occur
among young children in sub-Saharan Africa but pregnant
women and their unborn children living in Africa are also
very vulnerable to malaria. Infection with malaria during
pregnancy can cause severe maternal anemia (reduced red
blood cell numbers), stillbirths, and pre-term and low-
birthweight babies, and is responsible for the deaths of
many African babies and women. To prevent this loss of life,
the World Health Organization (WHO) recommends a three-
pronged approach—the delivery to pregnant women of the
antimalarial drug sulfadoxine-pyrimethamine (SP) at each
scheduled antenatal care visit given at least one month apart
(intermittent preventive treatment in pregnancy; IPTp), the
use of insecticide treated bed nets to protect pregnant
women from the bites of infected mosquitoes, and effective
case management of pregnant women with malarial illness.
Why Was This Study Done? IPTp with SP reduces the
delivery of low-birth-weight babies and neonatal deaths
but malaria parasites are becoming resistant to SP. Thus,
other antimalarial drugs need to be evaluated for use in
IPTp. Suitable drugs need to remain in the body for a long
time to maximize their prophylactic (preventative) effect,
they need to be given as a single dose at antenatal clinic
visits to ensure compliance, and they must not harm the
unborn child. In this open-label, randomized controlled
trial (RCT), the researchers compare the efficacy and
safety of IPTp with SP and mefloquine (MQ, an antima-
larial drug that matches these criteria) in HIV-negative
women living in Africa. The study also compares the
tolerability of two MQ regimens. RCTs compare outcomes
in groups of people chosen to receive different interven-
tions through the play of chance; in open-label RCTs,
both the researchers and the study participants know
which treatment is being administered. IPTp with SP is
only recommended for HIV-negative women because SP
interacts with cotrimoxazole, which is routinely given to
HIV-positive individuals to prevent infections.
What Did the Researchers Do and Find? The researchers
assigned 4,749 pregnant women in Benin, Gabon, Mozam-
bique, and Tanzania to one of three study groups.
Participants in the SP and MQ groups received two doses
of SP or MQ, respectively, administered at least one month
apart. Participants in the split-dose MQ group received each
MQ dose as half doses given on consecutive days. The
prevalence of low-birth-weight deliveries (the study’s prima-
ry outcome; the prevalence of a condition is the proportion
of a population with that condition) was similar in the SP
group and in the combined MQ groups. However, compared
to women who received SP, women who received MQ had a
lower risk of parasitemia (parasites in the blood), a lower risk
of anemia at delivery, fewer episodes of clinical malaria, and
fewer outpatient attendances. The prevalence of placental
infection with malaria parasites and of adverse pregnancy
outcomes such as stillbirth was similar in all the study
groups. Finally, the tolerability of IPTp was poorer in the two
MQ intervention groups than in the SP group, but similar
proportions of adverse events (mainly dizziness and vomit-
ing) were reported for the two MQ dosing regimens.
What Do These Findings Mean? These findings indicate
that HIV-negative African women taking MQ for IPTp had a
similar risk of a low-birth-weight delivery (the study’s primary
outcome) and lower risk of malaria illness during pregnancy
than women taking SP for IPTp. Because the study did not
have a no-IPTp arm (for ethical reasons), these findings
provide no information about the efficacy or safety or either
MQ or SP per se; these findings only indicate that MQ is no
more efficacious than SP in the prevention of low-birth-
weight babies. Moreover, because the study was open-label,
the accuracy of the findings related to the tolerability and
safety of MQ compared to SP may be limited because of
biases in the assessment of safety outcomes. Given that the
MQ dose used here for IPTp was associated with poorer
tolerability than that of SP, these findings do not support the
use of MQ instead of SP for IPTp.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001733.
N A related PLOS Medicine Research Article by Raquel
Gonza´lez and colleagues examines IPTp-MQ in HIV-
infected women receiving cotrimoxazole prophylaxis
N This study is further discussed in a PLOS Medicine
Perspective by Richard Steketee.
N Information is available from the World Health Organiza-
tion on malaria (in several languages) and on malaria in
pregnancy; information on IPTp and the updated WHO
policy recommendation on IPTp with SP are available; the
2013 World Malaria Report provides details of the current
global malaria situation
N The US Centers for Disease Control and Prevention also
provides information on malaria; a personal story about
malaria in pregnancy is available
N Information is available from the Roll Back Malaria
Partnership on all aspects of global malaria control,
including information on malaria in pregnancy
N The Malaria in Pregnancy Consortium is undertaking
research into the prevention and treatment of malaria in
pregnancy
N MedlinePlus provides links to additional information on
malaria (in English and Spanish)
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